Novartis Announced New Data From ALITHIOS Open-label Extension Study, Showing First-line Kesimpta (Ofatumumab) Treatment For Up To Six Years Led To Less Disability And Disease Progression In Recently Diagnosed And Treatment-naïve Relapsing Multiple Sclerosis Patients Vs. Those Who Switched From Teriflunomide
Portfolio Pulse from Benzinga Newsdesk
Novartis has released new data from the ALITHIOS study, indicating that first-line treatment with Kesimpta (Ofatumumab) for up to six years results in less disability and disease progression in relapsing multiple sclerosis patients compared to those who switched from Teriflunomide.
September 18, 2024 | 10:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' new data from the ALITHIOS study highlights the long-term benefits of Kesimpta in treating relapsing multiple sclerosis, potentially boosting its market position and impacting stock positively.
The positive results from the ALITHIOS study enhance the perceived efficacy of Kesimpta, potentially increasing its adoption in the MS treatment market. This could lead to higher revenues for Novartis, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90